Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
Active, not recruiting · NCT04938232 · Registry updated 2026-09-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL | Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-09-16 | NCT04938232 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Dana-Farber Cancer Institute | 324 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brigham and Women's Hospital | Boston | United States | 511 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| University of Chicago Medicine | Chicago | United States | 27 |